Use of otilonium bromide in the treatment of abdominal pain
https://doi.org/10.21518/ms2026-185
Abstract
Abdominal pain is a fairly common clinical problem encountered by clinicians. The causes of abdominal pain can be varied (both functional and organic). Abdominal pain is a fairly common clinical problem and is a serious issue in internal medicine and gastroenterology. Abdominal pain is the primary symptom of irritable bowel syndrome (IBS) and is primarily associated with intestinal smooth muscle spasm. However, abdominal pain caused by spasm can also occur with other conditions, such as biliary system disorders, specifically functional disorders of the gallbladder and sphincter of Oddi, and painful colonic spasms associated with IBS-like symptoms associated with underlying organic bowel pathology in remission (diverticular disease, inflammatory bowel disease in remission, and others). Antispasmodics are the drugs of choice for abdominal pain with a spastic component. The domestic pharmaceutical market offers various classes of antispasmodics, including selective calcium channel blockers. One such selective calcium channel blocker is otilonium bromide, which is widely used worldwide. It is effective, well-tolerated, and superior to placebo in reducing symptoms and preventing pain recurrence in patients with both IBS and other intestinal spasticity. The drug’s selective action and low intestinal absorption result in minimal side effects and the potential for otilonium bromide use in patients with comorbidities, including long-term use. This article presents two clinical cases of abdominal pain: a female patient with a long history of IBS and a patient with uncomplicated diverticular disease with IBS-like manifestations. These cases highlight the potential use of otilonium bromide.
About the Author
I. G. Pakhomova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Inna G. Pakhomova - Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy with Clinic.
2, Akkuratov St., St Petersburg, 197341
References
1. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114. https://doi.org/10.1053/j.gastro.2020.04.014.
2. Ивашкин ВТ, Шелыгин ЮА, Баранов АА, Намазова-Баранова ЛС, Ачкасов СИ, Алексеева ОП и др. Синдром раздраженного кишечника: клинические рекомендации. М.; 2024. 64 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/892_1.
3. Ивашкин ВТ, Шептулин АА. Боли в животе. М.: МЕДпресс-информ; 2012. 112 с.
4. Lindberg G, Mohammadian G. Loose ends in the differential diagnosis of IBS-like symptoms. Front Med. 2023;10:1141035. https://doi.org/10.3389/fmed.2023.1141035.
5. Yu V, Ballou S, Hassan R, Singh P, Shah E, Rangan V et al. Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders. Am J Gastroenterol. 2021;116(8):1720–1726. https://doi.org/10.14309/ajg.0000000000001306.
6. Yakovenko EP, Yakovenko AV, Agafonova NA, Ivanov AN, Pryanishnikova AS, Popova EV, Grigorieva SW. Abdominal pain: mechanisms of formation, rational approach to the choice of therapy. RMJ. 2009;(2):48–53. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Abdominalynye_boli_mehanizmy_formirovaniya_racionalynyy_podhod_k_vyboru_terapii/.
7. Weinstein WM, Hawkey CJ, Bosch J. Clinical Gastroenterology and Hepatology. Elsevie; 2005. 1191 p.
8. Pakhomova IG. Pathology of the colon: from functional to organic. Meditsinskiy Sovet. 2013;(5):46–53. (In Russ.) https://doi.org/10.21518/2079-701X-2013-5-46-53.
9. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917. https://doi.org/10.1016/S2468-1253(20)30217-X.
10. Triantafillidis JK, Malgarinos G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review. Clin Exp Gastroenterol. 2014;7:75–82. https://doi.org/10.2147/CEG.S46291.
11. Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome Aliment Pharmacol Ther. 2011;34(4):432–442. https://doi.org/10.1111/j.1365-2036.2011.04730.x.
12. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14(12):1331–1338. https://doi.org/10.1097/00042737-200212000-00008.
13. Weiser T. Guideline recommendations for the treatment of abdominal pain (in irritable bowel syndrome). EFSM. 2021;1:210010. https://doi.org/10.52778/efsm.21.0010.
14. Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(Suppl. 2):1–18. https://doi.org/10.1038/s41395-018-0084-x.
15. Carmona-Sánchez R, Icaza-Chávez ME, Bielsa-Fernández MV, Gómez-Escudero O, Bosques-Padilla F, Coss-Adame E et al. The Mexican consensus on irritable bowel syndrome. Rev Gastroenterol Mex. 2016;81(3):149–167. https://doi.org/10.1016/j.rgmx.2016.01.004.
16. Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24(2):197–215. https://doi.org/10.5056/jnm17145.
17. Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011;49(2):237–293. https://doi.org/10.1055/s-0029-1245976.
18. Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018;13(4):259–288. https://doi.org/10.5114/pg.2018.78343.
19. Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E et al. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363. https://doi.org/10.17235/reed.2016.4389/2016.
20. Khrutskaya MS, Semenyako SV, Bobrovskaya EI, Parfenenko TV. Еffect of otilonium bromide on intensity of chronic abdominal pain. Meditsinskie Novosti. 2014;(3):59–61. (In Russ.) Available at: https://www.elibrary.ru/salivv.
21. Zhou L, She P, Tan F, Li S, Zeng X, Chen L et al. Repurposing Antispasmodic Agent Otilonium Bromide for Treatment of Staphylococcus aureus Infections. Front Microbiol. 2020;11:1720. https://doi.org/10.3389/fmicb.2020.01720.
22. Zhen C, Wang L, Feng Y, Whiteway M, Hang S, Yu J et al. Otilonium Bromide Exhibits Potent Antifungal Effects by Blocking Ergosterol Plasma Membrane Localization and Triggering Cytotoxic Autophagy in Candida Albicans. Adv Sci. 2024;11(35):e2406473. https://doi.org/10.1002/advs.202406473.
23. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–6043. https://doi.org/10.3748/wjg.v20.i20.6031.
24. Clavé P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Ther Adv Gastroenterol. 2017;10(3):311–322. https://doi.org/10.1177/1756283X16681708.
Review
For citations:
Pakhomova IG. Use of otilonium bromide in the treatment of abdominal pain. Meditsinskiy sovet = Medical Council. 2026;(8):164-169. (In Russ.) https://doi.org/10.21518/ms2026-185
Views:
60
JATS XML
Email this article 